A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer
- 30 June 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 183 (6), 2219-2226
- https://doi.org/10.1016/j.juro.2010.02.020
Abstract
High-dose ketoconazole and docetaxel have shown activity as single agents against castration-resistant prostate cancer (CRPC). The goal of this phase I study was to determine the maximum tolerated doses, side effects, and pharmacokinetic interaction of coadministered docetaxel and ketoconazole. Patients with metastatic CRPC received weekly docetaxel for 3 of every 4 weeks, plus daily ketoconazole. Pharmacokinetic studies were performed on day 1 (docetaxel alone) and day 16 (after ketoconazole). The study enrolled 42 patients at 9 different dose levels. The combination regimens investigated included docetaxel weekly for three weeks out of four escalating from 5 to 43 mg/m2, with starting doses of ketoconazole of 600, 800, or 1200 mg/day. Declines in prostate-specific antigen of ≥ 50% were seen in 62% of patients. Of 25 patients with soft tissue disease, 7 (28%) had partial response. Median overall survival was 22.8 months, and was significantly greater in docetaxel-naïve patients than in patients pretreated with docetaxel (36.8 vs. 10.3 months; P = 0.0001). The most frequently observed adverse events were anemia, edema, fatigue, diarrhea, nausea, sensory neuropathy, and elevated liver function tests. The fractional change in docetaxel clearance correlated significantly with ketoconazole exposure (P < 0.01). Concomitant ketoconazole increased docetaxel exposure 2.6-fold with 1200 mg/day, 1.6-fold with 800 mg/day, and 1.3- to 1.5-fold with 600 mg/day. Results suggest that the combination of weekly docetaxel and ketoconazole has significant antitumor activity in CRPC with manageable toxicities. The extremely long survival in the docetaxel-naïve cohort (36.8 months) warrants additional larger trials of docetaxel with ketoconazole or possibly CYP17A1 inhibitors such as abiraterone.Keywords
This publication has 41 references indexed in Scilit:
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with DocetaxelClinical Cancer Research, 2008
- Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic CancerClinical Cancer Research, 2008
- Prostate cancerThe Lancet, 2008
- Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains UnchangedAntimicrobial Agents and Chemotherapy, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of DocetaxelClinical Cancer Research, 2006
- Bioequivalence evaluation of two brands of ketoconazole tablets (Onofin‐K® and Nizoral®) in a healthy female Mexican populationBiopharmaceutics & Drug Disposition, 2004
- Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Journal of Clinical Oncology, 2004
- In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3Cancer Letters, 1997
- Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in manJournal of Antimicrobial Chemotherapy, 1983